In line with these data, miR-181a expression was decreased in BCR-ABL-expressing Lin−Sca-1+c-Kit+ (LSK) cells compared with control cells in the public database (GSE122432) (Fig. 1C); another set of data (GSE148567) showed that miR-181a expression was higher in CML patients underwent allogenetic transplantation than in newly diagnosed patients (Fig. 1D). The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.